Ticker: INDP

Indaptus Therapeutics, Inc. (NASDAQ: INDP) - Quick take Short summary: the company is a clinical‑stage biotech advancing its lead candidate Decoy20. Financially it's burning cash while raising capital through a SEPA, private placements and convertible notes; management completed a reverse split a...

Indaptus Therapeutics, Inc. (NASDAQ: INDP) Overview Indaptus Therapeutics is a clinical-stage biotechnology firm focused on developing an innovative anti-cancer and anti-viral immunotherapy. Their lead candidate, Decoy20, is advancing through clinical trials, placing it at the forefront of their ...